Principal Investigators

    Ifeachor, Professor E


    University of Plymouth

    Contact information of lead PI


    United Kingdom

    Title of project or programme

    Novel Point-of-Care Diagnostic Techniques for Dementia

    Source of funding information


    Total sum awarded (Euro)

    € 1,339,673

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Alzheimer's disease & other dementias


    Neurodegenerative disease in general

    Research Abstract

    The aim of this proposal is to create a new way, using multiplex graphene-based biosensors, for the detection of biomarkers found in biological fluids (e.g. blood, CSF, urine and saliva)
    in the early stages of dementia (with emphasis on Alzheimer’s disease) and changes in levels with disease progression.

    A generic, Point-of-Care (POC) biosensor technology, based on graphene transducers, has already been developed by one of the project partners and demonstrated for
    the detection of several disease biomarkers. Unlike existing analytical approaches, the sensor is a rapid diagnostic platform, yielding real-time data and a conclusive test
    result within minutes of the sample being taken. The idea is to combine this with novel electronic multiplex techniques and large area graphene to create a multiplexed
    biosensor array technology to enable the detection of multiple biomarkers of dementia simultaneously with the potential to significantly increase throughput.
    An objective of the project is to demonstrate a novel, low-cost, reliable, POC diagnostic platform, based on multiplex graphene biosensors, for early detection of
    dementia and following its progression from biological fluid such as blood.

    The development of a low cost, point-of-care biosensing technology that makes it possible to detect dementia, objectively, in the early stages and to
    monitor disease progression, rapidly, from a simple blood test would revolutionise diagnosis of dementia and have a huge positive impact on the selection of
    subjects for clinical trials for new drugs and for monitoring response to treatment.

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: United Kingdom
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF